AEON Biopharma, Inc.
ASE: AEONLive Quote
About AEON Biopharma, Inc.
Healthcare
Biotechnology
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.
📊 Fundamental Analysis
AEON Biopharma, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
At a current price of $0.84, AEON currently sits at the 43rd percentile of its 52-week range (Range: $0.38 - $1.45).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$18.85M
Trailing P/E
--
Forward P/E
-1.22
Beta (5Y)
0.73
52W High
$1.45
52W Low
$0.38
Avg Volume
135K
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App